For clinical trial supply services, see our clinical trials services. For the full range of ophthalmic manufacturing capabilities, explore our ophthalmic manufacturing services.
With continuous ophthalmic production since 1981 and an FDA approval track record going back to 1995, NextPharma’s Tampere site, operating as NextPharma Oy, is one of Europe’s most experienced dedicated sterile ophthalmic and otic manufacturing facilities.
If you are evaluating a European CDMO for BFS, 3P or preservative-free multidose manufacturing, discover NextPharma Tampere’s core capabilities, regulatory status, facility details, and how to start a conversation with the team.
The Tampere site has been part of the NextPharma Group since 2019 and is purpose-built for ophthalmic development and manufacturing across a range of sterile filling technologies.
Our investments into new capacity will allow us to supply close to 1 bn single-dose ampoules and up to 50 Mio MD bottles. Our core technology platforms cover:
Blow-fill-seal (BFS) unidose and multidose
Three-piece (3P) preserved
Preservative Free Multi-Dose (PFMD)
Product development services are fully integrated into the site: formulation development, analytical method development and validation, packaging material compatibility studies, GMP and non-GMP lab-scale manufacturing, clinical trial supply, pilot and production scale-up, and registration batch manufacturing are all available at NextPharma Tampere, supporting programs from early feasibility through to commercial manufacture.
Microbiological QC: Sterility testing, LAL/bacterial endotoxin, bioburden, AET, PFMD development testing
Chemical QC: Release and stability testing, HPLC/UPLC, GC, particle analysis, osmolality, FTIR and full pharmacopoeia testing
Stability studies: ICH-compliant chambers across five temperature/humidity conditions for semi-permeable containers
Clinical trial labelling & packaging: All necessary parts for your trials
QP release & global distribution: Within the NextPharma group
For clinical trial supply services, see our clinical trials services. For the full range of ophthalmic manufacturing capabilities, explore our ophthalmic manufacturing services.
Production at NextPharma Tampere operates, amongst others, under FDA, FIMEA (EU) and EAEU requirements. An ISO 14001 environmental management system and OHSAS 18001 occupational health and safety system have been in place since 2008.
The NextPharma Tampere site covers 80,450 m² of land with 18,380 m² of built area, including 1,160 m² of clean room space, 750 m² of chemical laboratory, and 387 m² of microbiological laboratory. Warehousing supports 1,204 pallet places for packaging materials and 897 pallet places for finished goods, both temperature controlled. For an overview of all our sites, visit the NextPharma locations hub.
Whether it's development, manufacturing or supply. Tell us about your project and our experts will get back to you.